The new facility is designed to support biopharma customers with applications and process development for the purification of biotherapeutic molecu...
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling ...
CellFE, a leader in microfluidics-based cell engineering, and Made Scientific, a leading cell therapy contract development and manufacturing organization...
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. Azenta, Inc.a...
Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a n...
xPloration Maximizes Impact for OmniAb’s Partners through Efficient and Precise Mining of Immunized Antibody Repertoires OmniAb, Inc. &n...
Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, announced that its collaboration par...
MaxisIT, a long-recognized provider of clinical data analytics platform for clinical trials, today announced its transformation into Maxis AI. This strat...
Biocom California, the association representing the California life science industry, and KoreaBIO, a life science trade association which seeks to solid...
Cytel, a global leader in evidence generation and data-driven decision-making, today announced a partnership with Nested Knowledge, a pioneer in AI-power...
UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission o...
Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer pati...
ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus standard gemcitabine/nab-paclitaxel chemotherapy had increased overall survival, progress...
© 2025 Biopharma Boardroom. All Rights Reserved.
